Author: admin

NSCLC Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NSCLC Pipeline. Dive into DelveInsight’s comprehensive report today! @ NSCLC Pipeline Outlook

Key Takeaways from the NSCLC Pipeline Report

  • In May 2025, Suzhou Junjing BioSciences Co., Ltd. announced a Phase II clinical study evaluating JS111 capsules (AP-L1898) as monotherapy in patients with advanced NSCLC harboring EGFR mutations.Approximately 3 to 42 treatment-naïve patients with EGFR mutation-positive locally advanced, metastatic, or recurrent NSCLC will be enrolled.Based on prior safety, PK, and efficacy data, two dose levels-160 mg QD and 240 mg QD-will be tested to assess safety, tolerability, PK, and preliminary efficacy, and to determine the recommended Phase II dose (RP2D), as referenced in Section 4.3.
  • In May 2025, AstraZeneca conducted a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
  • In May 2025, Revolution Medicines Inc. organized a Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.
  • In May 2025, Amgen announced a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
  • DelveInsight’s NSCLC Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for NSCLC treatment.
  • The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.
  • Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and others.

Stay ahead with the most recent pipeline outlook for NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ NSCLC Treatment Drugs

NSCLC Emerging Drugs Profile

  • AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

  • CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

NSCLC.

The NSCLC Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
  • NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market

Explore groundbreaking therapies and clinical trials in the NSCLC Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New NSCLC Drugs

NSCLC Companies

GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type

NSCLC Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type

Unveil the future of NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ NSCLC Market Drivers and Barriers

Scope of the NSCLC Pipeline Report

  • Coverage- Global
  • NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc. and others.
  • NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab, and others.
  • NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NSCLC Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NSCLC Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Late Stage Products (Pre Registration)
  9. AMG 510: Amgen
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Drug Name: Company Name
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. CMP 001: Cytos Biotechnology
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  19. Non-Small-Cell Lung cancer (NSCLC) Key Products
  20. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  21. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  22. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  23. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  24. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NSCLC Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Meningioma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Meningioma Pipeline Outlook

Key Takeaways from the Meningioma Pipeline Report

  • In May 2025, European Organisation for Research and Treatment of Cancer – EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine “theranostic” concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
  • In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.
  • DelveInsight’s Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
  • The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.

Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs

Meningioma Emerging Drugs Profile

  • Gleolan: NX Devolopment Corp

NX development corp.’s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction.

  • Nivolumab: Bristol-Myers Squibb

Bristol-Myers Squibb “breakthrough” drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response.

The Meningioma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment.
  • Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market

Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Meningioma Drugs

Meningioma Companies

NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.

Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Meningioma Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Meningioma Market Drivers and Barriers

Scope of the Meningioma Pipeline Report

  • Coverage- Global
  • Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
  • Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
  • Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Meningioma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Meningioma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Meningioma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Gleolan: Nx Development Corp.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Nivolumab: Bristol-Myers Squibb
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Meningioma Key Companies
  19. Meningioma Key Products
  20. Meningioma- Unmet Needs
  21. Meningioma- Market Drivers and Barriers
  22. Meningioma- Future Perspectives and Conclusion
  23. Meningioma Analyst Views
  24. Meningioma Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Uterine Leiomyosarcoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Uterine Leiomyosarcoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Uterine Leiomyosarcoma pipeline landscape. It covers the Uterine Leiomyosarcoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Uterine Leiomyosarcoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Uterine Leiomyosarcoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Uterine Leiomyosarcoma Pipeline Outlook

Key Takeaways from the Uterine Leiomyosarcoma Pipeline Report

  • In March 2025, UNICANCER announced a phase II trial designed to demonstrate whether adding 4 cycles of post-operative chemotherapy improves relapse-free survival as compared with follow-up (standard management) in patients with resected FIGO stage I uterine leiomyosarcoma, considered at high-risk according to CINSARC NanoCind® signature.
  • DelveInsight’s Uterine Leiomyosarcoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Uterine Leiomyosarcoma treatment.
  • The leading Uterine Leiomyosarcoma Companies such as Novartis, PharmMar, and others.
  • Promising Uterine Leiomyosarcoma Pipeline Therapies such as Doxorubicin, Trabectedin, gemcitabine + docetaxel, letrozole, Pazopanib, Carboplatin and others.

Stay ahead with the most recent pipeline outlook for Uterine Leiomyosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Uterine Leiomyosarcoma Treatment Drugs

Uterine Leiomyosarcoma Emerging Drugs Profile

  • Trabectedin: PharmMar

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

  • Letrozole: Novartis

Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone.8 In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels. Currently, in phase II of clinical trials.

The Uterine Leiomyosarcoma Pipeline Report Provides Insights into

 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Leiomyosarcoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Leiomyosarcoma Treatment.
  • Uterine Leiomyosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Uterine Leiomyosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Leiomyosarcoma market

Explore groundbreaking therapies and clinical trials in the Uterine Leiomyosarcoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Uterine Leiomyosarcoma Drugs

Uterine Leiomyosarcoma Companies

Novartis, PharmMar, and others.

Uterine Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Uterine Leiomyosarcoma Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Unveil the future of Uterine Leiomyosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Uterine Leiomyosarcoma Market Drivers and Barriers

Scope of the Uterine Leiomyosarcoma Pipeline Report

  • Coverage- Global
  • Uterine Leiomyosarcoma Companies- Novartis, PharmMar, and others.
  • Uterine Leiomyosarcoma Pipeline Therapies- Doxorubicin, Trabectedin, gemcitabine + docetaxel, letrozole, Pazopanib, Carboplatin and others.
  • Uterine Leiomyosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Uterine Leiomyosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Uterine Leiomyosarcoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Uterine Leiomyosarcoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Uterine Leiomyosarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Uterine Leiomyosarcoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Uterine Leiomyosarcoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Letrozole: Novartis
  13. Drug profiles in the detailed report…..
  14. Pre-clinical and Discovery Stage Products
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Uterine Leiomyosarcoma Key Companies
  18. Uterine Leiomyosarcoma Key Products
  19. Uterine Leiomyosarcoma- Unmet Needs
  20. Uterine Leiomyosarcoma- Market Drivers and Barriers
  21. Uterine Leiomyosarcoma- Future Perspectives and Conclusion
  22. Uterine Leiomyosarcoma Analyst Views
  23. Uterine Leiomyosarcoma Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/uterine-leiomyosarcoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uterine Leiomyosarcoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s “Central Nervous System Tumors Pipeline Insight 2025” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Tumors pipeline landscape. It covers the Central Nervous System Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Central Nervous System Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Central Nervous System Tumors Pipeline Outlook

Key Takeaways from the Central Nervous System Tumors Pipeline Report

  • In May 2025, Genmab announced a study will be conducted in two parts: Part 1 (dose-finding) and Part 2 (randomization). The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors.
  • In May 2025, Stemline Therapeutics Inc. announced a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
  • In May 2025, Hoffmann-La Roche organized a study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
  • DelveInsight’s Central Nervous System Tumors Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Central Nervous System Tumors treatment.
  • Promising Central Nervous System Tumors Companies such as Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
  • The leading Central Nervous System Tumors Pipeline Therapies such as Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.

Stay ahead with the most recent pipeline outlook for Central Nervous System Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Central Nervous System Tumors Treatment Drugs

Central Nervous System Tumors Emerging Drugs Profile

  • F520: Shandong New Time Pharmaceutical

F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma.

  • Tirabrutinib: Ono Pharmaceuticals

Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma.

The Central Nervous System Tumors Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Central Nervous System Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Central Nervous System Tumors Treatment.
  • Central Nervous System Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Central Nervous System Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Central Nervous System Tumors market

Explore groundbreaking therapies and clinical trials in the Central Nervous System Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Central Nervous System Tumors Drugs

Central Nervous System Tumors Companies

Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.

Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Central Nervous System Tumors Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Central Nervous System Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Central Nervous System Tumors Market Drivers and Barriers

Scope of the Central Nervous System Tumors Pipeline Report

  • Coverage- Global
  • Central Nervous System Tumors Companies- Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
  • Central Nervous System Tumors Pipeline Therapies- Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.
  • Central Nervous System Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Central Nervous System Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Central Nervous System Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Central Nervous System Tumors Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Central Nervous System Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Drug Name: Company Name
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. F520: Shandong New Time Pharmaceutical
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. PRT811: Prelude Therapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Central Nervous System Lymphoma Key Companies
  17. Central Nervous System Lymphoma Key Products
  18. Central Nervous System Lymphoma- Unmet Needs
  19. Central Nervous System Lymphoma- Market Drivers and Barriers
  20. Central Nervous System Lymphoma- Future Perspectives and Conclusion
  21. Central Nervous System Lymphoma Analyst Views
  22. Central Nervous System Lymphoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Pediatric Brain Tumors Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Pediatric Brain Tumors Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Brain Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pediatric Brain Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pediatric Brain Tumors Pipeline Outlook

Key Takeaways from the Pediatric Brain Tumors Pipeline Report

  • In May 2025, University of Florida announced the studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine patients with a spontaneous malignant glioma. In one arm of this study, we will investigate the safety and immunologic activity of RNA-LP vaccines in pediatric patients with recurrent pHGG.
  • In May 2025, GlaxoSmithKline conducted a study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants.
  • In May 2025, St. Jude Children’s Research Hospital organized studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH).
  • DelveInsight’s Pediatric Brain Tumors Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pediatric Brain Tumors treatment.
  • Promising Pediatric Brain Tumors Companies such as Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
  • The leading Pediatric Brain Tumors Pipeline Therapies such as Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.

Stay ahead with the most recent pipeline outlook for Pediatric Brain Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pediatric Brain Tumors Treatment Drugs

Pediatric Brain Tumors Emerging Drugs Profile

  • MTX110: Biodexa Pharmaceuticals

MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD) that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favorable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG and recurrent medulloblastoma and preclinical for treatment of glioblastoma. MTX110 is delivered directly into and around the patient’s tumor via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumor to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumor cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines. Currently, the drug is in Phase I/II stage of its development for the treatment of diffuse intrinsic pontine glioma.

  • Iopofosine: Cellectar Biosciences

Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. Iopofosine is currently being evaluated in the CLOVER-WaM Phase II pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase IIb study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase I study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM. Currently, the drug is in Phase I stage of its development for the treatment of pediatric brain tumor.

The Pediatric Brain Tumors Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pediatric Brain Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pediatric Brain Tumors Treatment.
  • Pediatric Brain Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pediatric Brain Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pediatric Brain Tumors market

Explore groundbreaking therapies and clinical trials in the Pediatric Brain Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Pediatric Brain Tumors Drugs

Pediatric Brain Tumors Companies

Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.

Pediatric Brain Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Pediatric Brain Tumors Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Pediatric Brain Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pediatric Brain Tumors Market Drivers and Barriers

Scope of the Pediatric Brain Tumors Pipeline Report

  • Coverage- Global
  • Pediatric Brain Tumors Companies- Biodexa Pharmaceuticals, Cellectar Biosciences, ZIOPHARM Oncology, Y-mAbs Therapeutics Inc., Neonc Technologiesd Inc. and others.
  • Pediatric Brain Tumors Pipeline Therapies- Doxorubicin, temozolomide, thalidomide, tozuleristide, plerixafor, CX 4945, Abemaciclib and others.
  • Pediatric Brain Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pediatric Brain Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pediatric Brain Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pediatric Brain Tumors Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Pediatric Brain Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pediatric Brain Tumors – DelveInsight’s Analytical Perspective
  7. Drug profiles in the detailed report…..
  8. Late Stage Products (Phase III)
  9. Drug Name: Company Name
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Drug Name: Company Name
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I/II)
  15. Comparative Analysis
  16. MTX110: Biodexa Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Pre-clinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Pediatric Brain Tumors Key Companies
  23. Pediatric Brain Tumors Key Products
  24. Pediatric Brain Tumors- Unmet Needs
  25. Pediatric Brain Tumors- Market Drivers and Barriers
  26. Pediatric Brain Tumors- Future Perspectives and Conclusion
  27. Pediatric Brain Tumors Analyst Views
  28. Pediatric Brain Tumors Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pediatric-brain-tumors-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pediatric Brain Tumors Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the MALT Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the MALT Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ MALT Lymphoma Pipeline Outlook

Key Takeaways from the MALT Lymphoma Pipeline Report

  • In May 2025, Incyte Corporation announced a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
  • In May 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin ‘s lymphoma (NHL).
  • In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
  • DelveInsight’s MALT Lymphoma Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for MALT Lymphoma treatment.
  • Promising MALT Lymphoma Companies such as MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
  • The leading MALT Lymphoma Pipeline Therapies such as Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.

Stay ahead with the most recent pipeline outlook for MALT Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ MALT Lymphoma Treatment Drugs

MALT Lymphoma Emerging Drugs Profile

  • Tafasitamab: Incyte

Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of Malt Lymphoma.

The MALT Lymphoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of MALT Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for MALT Lymphoma Treatment.
  • MALT Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • MALT Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the MALT Lymphoma market

Explore groundbreaking therapies and clinical trials in the MALT Lymphoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New MALT Lymphoma Drugs

MALT Lymphoma Companies

MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.

Malt Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Small Molecule
  • Gene Therapy
  • Peptide
  • Immunotherapy
  • Cell Therapy

MALT Lymphoma Products have been categorized under various Molecule types such as

  • Intravenous
  • Intradermal
  • Oral
  • Subcutaneous
  • Intramuscular

Unveil the future of MALT Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ MALT Lymphoma Market Drivers and Barriers

Scope of the MALT Lymphoma Pipeline Report

  • Coverage- Global
  • MALT Lymphoma Companies- MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
  • MALT Lymphoma Pipeline Therapies- Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
  • MALT Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • MALT Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on MALT Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ MALT Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Malt Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Malt Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tafasitamab: Incyte
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Mosunetuzumab: Genentech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. BGB-10188: BeiGene
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. PSB202: Sound Biologics
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Malt Lymphoma Key Companies
  24. Malt Lymphoma Key Products
  25. Malt Lymphoma – Unmet Needs
  26. Malt Lymphoma – Market Drivers and Barriers
  27. Malt Lymphoma – Future Perspectives and Conclusion
  28. Malt Lymphoma Analyst Views
  29. Malt Lymphoma Key Companies
  30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malt-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Castrate Resistant Prostrate Cancer Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Castrate Resistant Prostrate Cancer Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook

Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report

  • In May 2025, Pfizer announced a study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician’s choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.
  • In May 2025, Bayer conducted a study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy.
  • In May 2025, Novartis Pharmaceuticals organized a study is to assess the efficacy, tolerability, safety, pharmacokinetic (PK) and dosimetry of 177Lu-PSMA-617, in participants with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in Japan. Furthermore, the safety, PK and dosimetry of 68Ga-PSMA-11 (PSMA imaging agent) are assessed in the same study.
  • In May 2025, Janssen Research & Development LLC announced a study that consists of 4 phases: a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), a Follow-up Phase (every 3 months after end of treatment visit), and a Long-term Extension Phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment). Participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.
  • In May 2025, Celgene conducted a study is to compare the efficacy and safety of BMS-986365 versus the investigator’s choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
  • DelveInsight’s Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
  • The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
  • Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.

Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs

Castrate Resistant Prostrate Cancer Emerging Drugs

  • Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

  • Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

The Castrate Resistant Prostrate Cancer Pipeline analysis report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Castrate Resistant Prostrate Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Castrate Resistant Prostrate Cancer Treatment.
  • Castrate Resistant Prostrate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Castrate Resistant Prostrate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Castrate Resistant Prostrate Cancer market.

Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs

Castrate Resistant Prostrate Cancer Companies

Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.

Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers

Scope of the Castrate Resistant Prostrate Cancer Pipeline Report

  • Coverage- Global
  • Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
  • Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
  • Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Castrate Resistant Prostrate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Castrate Resistant Prostrate Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Niraparib: Janseen
  11. Mid Stage Products (Phase II)
  12. ZEN003694: Newsoara Biopharma
  13. Early Stage Products (Phase I)
  14. EPI7386: ESSA Pharma
  15. Pre-clinical and Discovery Stage Products
  16. Drug Name: Company Name
  17. Inactive Products
  18. Castrate Resistant Prostrate Cancer Key Companies
  19. Castrate Resistant Prostrate Cancer Key Products
  20. Castrate Resistant Prostrate Cancer- Unmet Needs
  21. Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
  22. Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
  23. Castrate Resistant Prostrate Cancer Analyst Views
  24. Castrate Resistant Prostrate Cancer Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/castrate-resistant-prostrate-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Castrate Resistant Prostrate Cancer Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Intratumoral Cancer Treatment Market”
Intratumoral Cancer Therapies Companies are Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others

(Albany, USA) DelveInsight’s “Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Intratumoral Cancer Therapies market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Intratumoral Cancer Therapies market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Intratumoral Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Intratumoral Cancer Therapies market.

 

To Know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intratumoral Cancer Therapies Market Forecast

 

Some of the key facts of the Intratumoral Cancer Therapies Market Report:

  • The Intratumoral Cancer Therapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In January 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company dedicated to discovering and developing proprietary immune-based intratumoral cancer therapies, has provided a business update showcasing significant progress with its lead drug candidate, INT230-6.
  • In January 2025, Lokon Pharma AB reported that the U.S. FDA granted Fast Track designation for the company’s product candidate LOAd703 in the treatment of pancreatic cancer.
  • In March 2024, ImmVira announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its oncolytic virus product MVR-T3011 IT (intratumoral injection) for treating recurrent or metastatic head and neck squamous cell cancer that has progressed after platinum-based chemotherapy and at least one prior line of anti-PD1/PDL1 therapy.
  • Several intratumoral therapy strategies, such as immune-enhancing cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, oncolytic viruses (OVs), and plasmid DNA, are currently undergoing clinical development for melanoma patients.
  • At present, IMLYGIC is the only intratumoral therapy approved by the US FDA for melanoma treatment, capturing over 90% of the total market for intratumoral therapies.
  • Among the emerging therapies, OncoSec Medical’s TAVO (tavokinogene telseplasmid), a plasmid-based interleukin-12, is anticipated to generate the highest revenue.
  • The United States holds around 80% of the market share for Intratumoral Cancer Therapies.
  • A person’s chance of surviving five years after being diagnosed with cutaneous melanoma improves with earlier diagnosis. Skin melanoma is diagnosed in 81.6% of cases at the local stage, 9% at the regional stage, and 4% at the distant stage when the cancer has spread. Skin-related localised melanoma had a 5-year relative survival rate of 99.5%
  • During the prediction period (2021-2022), the United States reported 98,046 instances of melanoma; this number is expected to rise to 2032. In 2021, there were 31,636 cases of melanoma and 91,650 cases of non-melanoma skin cancer (NMSC) in Germany
  • Nonmelanoma skin cancer (NMSC), one of the nine primary indications for intratumoral treatments, represented the majority of cases in the 7MM. In 2021, there were 793,007 NMSC instances in the 7MM as a whole
  • Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
  • Key Intratumoral Cancer Therapies Therapies: IMLYGIC (talimogene laherparepvec), DELYTACT (G47Δ), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
  • The Intratumoral Cancer Therapies market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intratumoral Cancer Therapies pipeline products will significantly revolutionize the Intratumoral Cancer Therapies market dynamics.

 

Intratumoral Cancer Therapies Overview

Intratumoral cancer therapies represent a novel and promising approach in oncology, focusing on the direct injection of therapeutic agents into the tumor microenvironment. Unlike systemic therapies that circulate throughout the body, intratumoral cancer therapies aim to maximize local tumor control while minimizing systemic toxicity. This targeted method enhances the concentration of the drug within the tumor, improving efficacy and reducing side effects.

Intratumoral cancer therapies include a range of modalities such as oncolytic viruses, immunotherapies, cytokines, gene therapies, and small molecule drugs. These therapies are designed to stimulate a localized immune response that can also generate systemic anti-tumor immunity, potentially leading to tumor regression at distant sites – a phenomenon known as the abscopal effect.

Intratumoral cancer therapies are gaining traction in clinical trials for various cancers, including melanoma, head and neck cancers, and triple-negative breast cancer. Their ability to modulate the tumor microenvironment and enhance immune cell infiltration makes them a key player in combination strategies with checkpoint inhibitors and other immuno-oncology treatments.

Despite their potential, intratumoral cancer therapies face challenges such as optimal delivery methods, tumor accessibility, and standardization of treatment protocols. Ongoing research and technological advancements are expected to overcome these hurdles and drive future growth in this field.

 

Get a Free sample for the Intratumoral Cancer Therapies Market Report – https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight

 

Intratumoral Cancer Therapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Intratumoral Cancer Therapies Epidemiology Segmentation:

The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

  • Total Prevalence of Intratumoral Cancer Therapies
  • Prevalent Cases of Intratumoral Cancer Therapies by severity
  • Gender-specific Prevalence of Intratumoral Cancer Therapies
  • Diagnosed Cases of Episodic and Chronic Intratumoral Cancer Therapies

 

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ Intratumoral Cancer Therapies Epidemiology Forecast

 

Intratumoral Cancer Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intratumoral Cancer Therapies market or expected to get launched during the study period. The analysis covers Intratumoral Cancer Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intratumoral Cancer Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Intratumoral Cancer Therapies Therapies and Key Companies

  • IMLYGIC (talimogene laherparepvec): Amgen
  • DELYTACT (G47Δ): Daiichi Sankyo
  • AIV001: AiViva BioPharma
  • LTX-315: Lytix Biopharma
  • Vidutolimod + nivolumab: Regeneron Pharmaceuticals
  • Vidutolimod (CMP-001): Checkmate Pharmaceuticals
  • Tavo (tavokinogene telseplasmid): OncoSec Medical Incorporated
  • CAVATAK (V937; CVA21): Merck
  • PVSRIPO (PVS-RIPO): Istari Oncology
  • RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
  • Daromun (Nidlegy): Philogen
  • Cotsiranib (STP705): Sirnaomics
  • Cavrotolimod (AST-008): Exicure
  • INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
  • NanoPac (LSAM paclitaxel): NanOlogy
  • Hensify (NBTXR3/ PEP503): Nanobiotix
  • AlloStim: Immunovative Therapies
  • Tasadenoturev (DNX-2401): DNAtrix
  • Tilsotolimod (IMO-2125): Idera Pharmaceuticals
  • Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
  • G207: Treovir
  • Intuvax (Ilixadencel): Immunicum

 

 

Discover more about therapies set to grab major Intratumoral Cancer Therapies market share @ Intratumoral Cancer Treatment Market

 

Scope of the Intratumoral Cancer Therapies Market Report

  • Study Period: 2020-2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
  • Key Intratumoral Cancer Therapies Therapies: IMLYGIC (talimogene laherparepvec), DELYTACT (G47Δ), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
  • Intratumoral Cancer Therapies Therapeutic Assessment: Intratumoral Cancer Therapies current marketed and Intratumoral Cancer Therapies emerging therapies
  • Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market drivers and Intratumoral Cancer Therapies market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Intratumoral Cancer Therapies Unmet Needs, KOL’s views, Analyst’s views, Intratumoral Cancer Therapies Market Access and Reimbursement

 

To know more about Intratumoral Cancer Therapies companies working in the treatment market, visit @ Intratumoral Cancer Therapies Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Intratumoral Cancer Therapies Market Report Introduction

2. Executive Summary for Intratumoral Cancer Therapies

3. SWOT analysis of Intratumoral Cancer Therapies

4. Intratumoral Cancer Therapies Patient Share (%) Overview at a Glance

5. Intratumoral Cancer Therapies Market Overview at a Glance

6. Intratumoral Cancer Therapies Disease Background and Overview

7. Intratumoral Cancer Therapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Intratumoral Cancer Therapies

9. Intratumoral Cancer Therapies Current Treatment and Medical Practices

10. Intratumoral Cancer Therapies Unmet Needs

11. Intratumoral Cancer Therapies Emerging Therapies

12. Intratumoral Cancer Therapies Market Outlook

13. Country-Wise Intratumoral Cancer Therapies Market Analysis (2020-2034)

14. Intratumoral Cancer Therapies Market Access and Reimbursement of Therapies

15. Intratumoral Cancer Therapies Market Drivers

16. Intratumoral Cancer Therapies Market Barriers

17. Intratumoral Cancer Therapies Appendix

18. Intratumoral Cancer Therapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

Metastatic Cutaneous Squamous Cell Cancer Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Metastatic Cutaneous Squamous Cell Cancer Treatment Market”
Metastatic Cutaneous Squamous Cell Cancer Companies are Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.

(Albany, USA) DelveInsight’s “Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032” report delivers an in-depth understanding of the Metastatic Cutaneous Squamous Cell Cancer, historical and forecasted epidemiology as well as the Metastatic Cutaneous Squamous Cell Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Metastatic Cutaneous Squamous Cell Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Metastatic Cutaneous Squamous Cell Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Metastatic Cutaneous Squamous Cell Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Metastatic Cutaneous Squamous Cell Cancer market.

 

DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Metastatic Cutaneous Squamous Cell Cancer Therapeutics Market Outlook

 

Key Takeaways from the Metastatic Cutaneous Squamous Cell Cancer Market Report

  • In April 2025, Hummingbird Bioscience announced a phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers.
  • In April 2025, Merck Sharp & Dohme LLC conducted a study is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) pembrolizumab (+) berahyaluronidase alfa in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma or locally advanced unresectable cSCC. The primary hypothesis is that pembrolizumab (+) berahyaluronidase alfa will result in greater than 10% objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
  • In April 2025, Aulos Biosciences Inc. organized a phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with avelumab or nivolumab.
  • The increase in Metastatic Cutaneous Squamous Cell Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Metastatic Cutaneous Squamous Cell Cancer Market is anticipated to witness growth at a considerable CAGR.
  • The leading Metastatic Cutaneous Squamous Cell Cancer Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
  • Promising Metastatic Cutaneous Squamous Cell Cancer Pipeline Therapies such as Cemiplimab, RP1, INCB099280, Pembrolizumab, HMBD-001, Docetaxel, Cetuximab, CDK-002, AU-007, Aldesleukin, Avelumab and others.

 

Stay ahead in the competitive landscape of the Metastatic Cutaneous Squamous Cell Cancer Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Metastatic Cutaneous Squamous Cell Cancer Treatment Market Size

 

Metastatic Cutaneous Squamous Cell Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of Metastatic Cutaneous Squamous Cell Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Metastatic Cutaneous Squamous Cell Cancer epidemiology trends @ Metastatic Cutaneous Squamous Cell Cancer Prevalence

 

Metastatic Cutaneous Squamous Cell Cancer Drugs Market

The Metastatic Cutaneous Squamous Cell Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Metastatic Cutaneous Squamous Cell Cancer signaling in Metastatic Cutaneous Squamous Cell Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Metastatic Cutaneous Squamous Cell Cancer Treatment Market Landscape

The Metastatic Cutaneous Squamous Cell Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Metastatic Cutaneous Squamous Cell Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Metastatic Cutaneous Squamous Cell Cancer treatment guidelines, visit @ Metastatic Cutaneous Squamous Cell Cancer Market Drivers and Barriers

 

Metastatic Cutaneous Squamous Cell Cancer Companies

Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.

 

Metastatic Cutaneous Squamous Cell Cancer Market Outlook

The report’s outlook on the Metastatic Cutaneous Squamous Cell Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Metastatic Cutaneous Squamous Cell Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Metastatic Cutaneous Squamous Cell Cancer drug and late-stage pipeline therapy.

 

Metastatic Cutaneous Squamous Cell Cancer Drugs Uptake

The drug chapter of the Metastatic Cutaneous Squamous Cell Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Metastatic Cutaneous Squamous Cell Cancer.

 

Explore the dynamics of the Metastatic Cutaneous Squamous Cell Cancer Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Metastatic Cutaneous Squamous Cell Cancer Ongoing Clinical Trials Analysis

 

Scope of the Metastatic Cutaneous Squamous Cell Cancer Market Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Metastatic Cutaneous Squamous Cell Cancer Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
  • Metastatic Cutaneous Squamous Cell Cancer Pipeline Therapies- Cemiplimab, RP1, INCB099280, Pembrolizumab, HMBD-001, Docetaxel, Cetuximab, CDK-002, AU-007, Aldesleukin, Avelumab and others.
  • Metastatic Cutaneous Squamous Cell Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Metastatic Cutaneous Squamous Cell Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Cutaneous Squamous Cell Cancer Market Access and Reimbursement

 

Table of Contents

1. Key Insights

2. Executive Summary of Metastatic Cutaneous Squamous Cell Cancer

3. Competitive Intelligence Analysis for Metastatic Cutaneous Squamous Cell Cancer

4. Metastatic Cutaneous Squamous Cell Cancer: Market Overview at a Glance

5. Metastatic Cutaneous Squamous Cell Cancer: Disease Background and Overview

6. Metastatic Cutaneous Squamous Cell Cancer Patient Journey

7. Metastatic Cutaneous Squamous Cell Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Metastatic Cutaneous Squamous Cell Cancer Unmet Needs

10. Key Endpoints of Metastatic Cutaneous Squamous Cell Cancer Treatment

11. Metastatic Cutaneous Squamous Cell Cancer Marketed Products

12. Metastatic Cutaneous Squamous Cell Cancer Emerging Therapies

13. Metastatic Cutaneous Squamous Cell Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Metastatic Cutaneous Squamous Cell Cancer Market Outlook

16. Access and Reimbursement Overview of Metastatic Cutaneous Squamous Cell Cancer

17. Metastatic Cutaneous Squamous Cell Cancer KOL Views

18. Metastatic Cutaneous Squamous Cell Cancer Market Drivers

19. Metastatic Cutaneous Squamous Cell Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Cutaneous Squamous Cell Cancer Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Statistics, Therapies, Prevalence, Companies by DelveInsight

Inflammatory Breast Cancer Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Inflammatory Breast Cancer Treatment Market”
Inflammatory Breast Cancer companies working in the market are Merck, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Pfizer, and several others.

(Albany, USA) DelveInsight’s “Inflammatory Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Inflammatory Breast Cancer, historical and forecasted epidemiology as well as the Inflammatory Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Inflammatory Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Inflammatory Breast Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Inflammatory Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Inflammatory Breast Cancer market.

 

Request for a Free Sample Report @ Inflammatory Breast Cancer Market Forecast

 

Some facts of the Inflammatory Breast Cancer Market Report are:

  • According to DelveInsight, Inflammatory Breast Cancer market size is expected to grow at a decent CAGR by 2032.
  • Leading Inflammatory Breast Cancer companies working in the market are Merck, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Pfizer, and several others.
  • In March 2025, the FDA approved durvalumab with gemcitabine and cisplatin as neoadjuvant therapy in certain solid tumors, offering insights for neoadjuvant IBC regimens.
  • Furthermore, a reformulated multidose vial of thiotepa for breast and ovarian cancers received FDA approval in April 2025, enhancing scheduling flexibility in cytotoxic regimens that may benefit inflammatory breast cancer patients.
  • In February 2025, the FDA accepted a biologics license application for HLX11, a PERJETA biosimilar for HER2-positive breast cancer, potentially expanding HER2-targeted options for IBC cohorts.

 

Inflammatory Breast Cancer Overview

Inflammatory Breast Cancer (IBC) is a rare and aggressive form of breast cancer that progresses rapidly and is often misdiagnosed due to its unusual symptoms. Inflammatory Breast Cancer symptoms typically include redness, swelling, warmth, and skin changes that resemble an infection or rash, rather than a distinct lump. Inflammatory Breast Cancer diagnosis often requires a combination of physical exams, imaging tests like mammograms or MRIs, and a biopsy to confirm the presence of cancer cells.

Inflammatory Breast Cancer treatment usually involves a multimodal approach, including chemotherapy, surgery, and radiation therapy. In many cases, Inflammatory Breast Cancer chemotherapy is administered before surgery to shrink the tumor, followed by a mastectomy and targeted radiation. Inflammatory Breast Cancer prognosis depends on how early it is detected and how well the cancer responds to treatment.

Inflammatory Breast Cancer survival rates are improving with advancements in targeted therapies and immunotherapy. However, due to its aggressive nature, Inflammatory Breast Cancer awareness and early detection remain critical.

Inflammatory Breast Cancer research continues to explore new treatments, aiming to improve outcomes and quality of life. For patients and caregivers, understanding Inflammatory Breast Cancer stages, risk factors, and support options is key to managing this challenging diagnosis effectively.

 

Do you know what will be the Inflammatory Breast Cancer market share in 7MM by 2032 @ Inflammatory Breast Cancer Treatment Market

 

Inflammatory Breast Cancer Market

The Inflammatory Breast Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Inflammatory Breast Cancer market trends by analyzing the impact of current Inflammatory Breast Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Inflammatory Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Inflammatory Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Inflammatory Breast Cancer market is driven by increasing awareness, advancements in diagnostic imaging technologies, and the development of targeted therapies and immunotherapies. Rising investments in oncology research and a growing pipeline of clinical trials focused on aggressive breast cancers further propel market growth. Additionally, improved healthcare infrastructure and expanding access to novel treatment options in emerging markets contribute to the positive momentum.

However, the Inflammatory Breast Cancer market faces significant barriers, including the rarity and aggressive nature of the disease, which often leads to delayed diagnosis and misidentification. High treatment costs, limited availability of specialized therapies, and insufficient awareness among healthcare professionals and patients in low-resource regions also hinder market expansion. Furthermore, regulatory challenges and the complexity of conducting trials in rare cancer populations pose additional obstacles to innovation and market entry.

According to DelveInsight, the Inflammatory Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Inflammatory Breast Cancer Epidemiology

The Inflammatory Breast Cancer epidemiology section provides insights into the historical and current Inflammatory Breast Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Inflammatory Breast Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

 

Interested to know how the emerging diagnostic approaches will be contributing in increased Inflammatory Breast Cancer diagnosed prevalence pool? Download report @ https://www.delveinsight.com/sample-request/inflammatory-breast-cancer-market

 

Inflammatory Breast Cancer Drugs Uptake

This section focuses on the uptake rate of the potential Inflammatory Breast Cancer drugs recently launched in the Inflammatory Breast Cancer market or expected to be launched in 2019-2032. The analysis covers the Inflammatory Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Inflammatory Breast Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Inflammatory Breast Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Inflammatory Breast Cancer Pipeline Development Activities

The Inflammatory Breast Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Inflammatory Breast Cancer key players involved in developing targeted therapeutics.

 

Download report to know which TOP 3 therapies will be capturing the largest Inflammatory Breast Cancer market share by 2032? Click here @ Inflammatory Breast Cancer Medication and Companies

 

Inflammatory Breast Cancer Therapeutics Assessment

Major key companies are working proactively in the Inflammatory Breast Cancer Therapeutics market to develop novel therapies which will drive the Inflammatory Breast Cancer treatment markets in the upcoming years are Merck, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Pfizer, and several others.

 

Discover recent advancements in the inflammatory breast cancer treatment landscape @ Inflammatory Breast Cancer Clinical Trials and FDA Approvals

 

Inflammatory Breast Cancer Report Key Insights

1. Inflammatory Breast Cancer Patient Population

2. Inflammatory Breast Cancer Market Size and Trends

3. Key Cross Competition in the Inflammatory Breast Cancer Market

4. Inflammatory Breast Cancer Market Dynamics (Key Drivers and Barriers)

5. Inflammatory Breast Cancer Market Opportunities

6. Inflammatory Breast Cancer Therapeutic Approaches

7. Inflammatory Breast Cancer Pipeline Analysis

8. Inflammatory Breast Cancer Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Inflammatory Breast Cancer Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Inflammatory Breast Cancer Competitive Intelligence Analysis

4. Inflammatory Breast Cancer Market Overview at a Glance

5. Inflammatory Breast Cancer Disease Background and Overview

6. Inflammatory Breast Cancer Patient Journey

7. Inflammatory Breast Cancer Epidemiology and Patient Population

8. Inflammatory Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Inflammatory Breast Cancer Unmet Needs

10. Key Endpoints of Inflammatory Breast Cancer Treatment

11. Inflammatory Breast Cancer Marketed Products

12. Inflammatory Breast Cancer Emerging Therapies

13. Inflammatory Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Inflammatory Breast Cancer Market Outlook (7 major markets)

16. Inflammatory Breast Cancer Access and Reimbursement Overview

17. KOL Views on the Inflammatory Breast Cancer Market

18. Inflammatory Breast Cancer Market Drivers

19. Inflammatory Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Breast Cancer Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight